In this context, it appears that the decrease of AAC1 expression (and AAC2 at a lower extent) might be used as a genetic marker, among other already context-specific characterized genes [81], for estimating/predicting the survival of patients affected by renal cancer or the aggressiveness of the investigated kidney cancers. The gene discussed is SLC25A5; the disease is kidney cancer.